{"id":50980,"date":"2025-01-23T16:05:52","date_gmt":"2025-01-23T10:35:52","guid":{"rendered":"https:\/\/www.equentis.com\/blog\/?p=50980"},"modified":"2025-01-21T17:42:34","modified_gmt":"2025-01-21T12:12:34","slug":"top-10-mid-cap-companies-2025","status":"publish","type":"post","link":"https:\/\/www.equentis.com\/blog\/top-10-mid-cap-companies-2025\/","title":{"rendered":"Top 10 Mid-Cap Companies 2025"},"content":{"rendered":"
<\/div>\n

Mid-cap companies are critical in bridging the gap between small-scale and large corporations. These firms often showcase high growth potential while maintaining financial stability. According to the Securities and Exchange Board of India<\/a> (SEBI<\/a>), mid-cap stocks are those that are ranked from 101st to 250th in terms of full market capitalization. Investors looking for insights can explore share market advisory services <\/a>for detailed guidance.<\/p>\n\n\n\n

Below, we look closely at ten standout mid-cap companies from the Nifty<\/a> Midcap 100 based on their financial metrics and charting higher per their market cap. If these companies continue to grow, they may become large-cap companies. <\/p>\n\n\n\n

For those evaluating options, a stock screener<\/a> is a useful tool. Additionally, some mid cap stocks that could be large cap<\/a> are worth exploring. Comprehensive details about mid cap stocks<\/a> can further assist in making informed decisions.<\/p>\n\n\n\n

Hindustan Zinc<\/strong><\/h2>\n\n\n\n
Metric<\/td>Value<\/td><\/tr>
CMP (Rs)<\/td>438.00<\/td><\/tr>
P\/E Ratio<\/a><\/td>21.01<\/td><\/tr>
Market Cap (Rs Cr)<\/td>184902.33<\/td><\/tr>
Dividend Yield (%)<\/td>6.63<\/td><\/tr>
Net Profit (Q2 FY25, Rs Cr)<\/td>2298.00<\/td><\/tr>
Quarterly Profit Variation (%)<\/td>35.80<\/td><\/tr>
Sales (Q2 FY25, Rs Cr)<\/td>8242.00<\/td><\/tr>
Quarterly Sales Variation (%)<\/td>21.35<\/td><\/tr>
ROCE<\/a> (%)<\/td>46.25<\/td><\/tr><\/tbody><\/table>
Source: Screener.in<\/a> (09-01-2025)<\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Hindustan Zinc is one of the prominent mid cap stocks in the Indian market. Its strong financial foundation represents a reliable option among mid market cap stocks. Its quarterly performance reflects robust growth. Hindustan Zinc has a current market price of Rs. 438.00 and a price-to-earnings (P\/E) ratio of 21.01. <\/p>\n\n\n\n

With a market capitalization of Rs. 1,84,902.33 crore, the company boasts a dividend yield of 6.63%, making it notable for consistent returns. In the Q2 FY25, Hindustan Zinc recorded a net profit of Rs. 2,298.00 crore, representing a 35.80% increase in profit compared to the previous quarter. Its quarterly sales stood at Rs. 8,242.00 crore, with a sales growth of 21.35%. The company\u2019s return on capital employed (ROCE) is an impressive 46.25%, showcasing its operational efficiency.<\/p>\n\n\n\n

Max Healthcare<\/strong><\/h2>\n\n\n\n
Metric<\/td>Value<\/td><\/tr>
CMP (Rs)<\/td>1206.30<\/td><\/tr>
P\/E Ratio<\/td>110.80<\/td><\/tr>
Market Cap (Rs Cr)<\/td>117336.56<\/td><\/tr>
Dividend Yield (%)<\/td>0.12<\/td><\/tr>
Net Profit (Q2 FY25, Rs Cr)<\/td>281.81<\/td><\/tr>
Quarterly Profit Variation (%)<\/td>1.85<\/td><\/tr>
Sales (Q2 FY25, Rs Cr)<\/td>1707.46<\/td><\/tr>
Quarterly Sales Variation (%)<\/td>25.26<\/td><\/tr>
ROCE (%)<\/td>16.00<\/td><\/tr><\/tbody><\/table>
Source: Screener.in<\/a> (09-01-2025)<\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Max Healthcare, another strong contender in the mid cap stocks segment, has shown consistent growth in its financial metrics. Its market performance places it among the top mid market cap stocks in the healthcare industry. Max Healthcare has a market price of Rs. 1206.30 and a P\/E ratio of 110.80, with a market capitalization of Rs. 1,17,336.56 crore. <\/p>\n\n\n\n

The company\u2019s dividend yield is relatively low at 0.12%. It reported a net profit of Rs. 281.81 crore in the latest quarter. The profit growth for the quarter was modest at 1.85%, while sales amounted to Rs. 1,707.46 crore, reflecting a sales growth of 25.26%. The return on capital employed (ROCE) for Max Healthcare stands at 16.00%.<\/p>\n\n\n\n

Indian Hotels Company<\/strong><\/h2>\n\n\n\n
Metric<\/td>Value<\/td><\/tr>
CMP (Rs)<\/td>822.80<\/td><\/tr>
P\/E Ratio<\/td>81.81<\/td><\/tr>
Market Cap (Rs Cr)<\/td>117112.99<\/td><\/tr>
Dividend Yield (%)<\/td>0.21<\/td><\/tr>
Net Profit (Q2 FY25, Rs Cr)<\/td>582.71<\/td><\/tr>
Quarterly Profit Variation (%)<\/td>87.82<\/td><\/tr>
Sales (Q2 FY25, Rs Cr)<\/td>1826.12<\/td><\/tr>
Quarterly Sales Variation (%)<\/td>27.42<\/td><\/tr>
ROCE (%)<\/td>15.11<\/td><\/tr><\/tbody><\/table>
Source: Screener.in<\/a> (09-01-2025)<\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Indian Hotels Company is a prominent name among mid cap stocks in the hospitality sector. It consistently performs well and is a key player in the mid market cap stocks category. Indian Hotels Company has a market price of Rs. 822.80 and a P\/E ratio of 81.81, with a market capitalization of Rs. 1,17,112.99 crore. The company reported a net profit of Rs. 582.71 crore in the Q2 FY25, an increase of 87.82% compared to the previous quarter. Quarterly sales were recorded at Rs. 1,826.12 crore, marking a sales growth of 27.42%. The company’s return on capital employed (ROCE) is 15.11%.<\/p>\n\n\n\n

Mankind Pharma<\/strong><\/h2>\n\n\n\n
Metric<\/td>Value<\/td><\/tr>
CMP (Rs)<\/td>2828.05<\/td><\/tr>
P\/E Ratio<\/td>58.27<\/td><\/tr>
Market Cap (Rs Cr)<\/td>116787.51<\/td><\/tr>
Dividend Yield (%)<\/td>0.00<\/td><\/tr>
Net Profit (Q2 FY25, Rs Cr)<\/td>634.43<\/td><\/tr>
Quarterly Profit Variation (%)<\/td>34.84<\/td><\/tr>
Sales (Q2 FY25, Rs Cr)<\/td>2529.74<\/td><\/tr>
Quarterly Sales Variation (%)<\/td>11.91<\/td><\/tr>
ROCE (%)<\/td>24.57<\/td><\/tr><\/tbody><\/table>
Source: Screener.in<\/a> (09-01-2025)<\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

As a leading pharmaceutical company, Mankind Pharma stands out among mid market cap stocks with its growth and performance. It continues to attract interest from those seeking dependable mid cap stocks. Mankind Pharma, with a market price of Rs. 2828.05 and a P\/E ratio of 58.27, has a market capitalization of Rs. 1,16,787.51 crore. The company reported a quarterly net profit of Rs. 634.43 crore, reflecting a profit growth of 34.84%. Its sales for the quarter stood at Rs. 2,529.74 crore, with a sales growth of 11.91%. Mankind Pharma\u2019s return on capital employed (ROCE) is 24.57%.<\/p>\n\n\n\n

CG Power & Industrial Solutions<\/strong><\/h2>\n\n\n\n
Metric<\/td>Value<\/td><\/tr>
CMP (Rs)<\/td>678.90<\/td><\/tr>
P\/E Ratio<\/td>116.03<\/td><\/tr>
Market Cap (Rs Cr)<\/td>103906.14<\/td><\/tr>
Dividend Yield (%)<\/td>0.19<\/td><\/tr>
Net Profit (Q2 FY25, Rs Cr)<\/td>219.63<\/td><\/tr>
Quarterly Profit Variation (%)<\/td>-1.77<\/td><\/tr>
Sales (Q2 FY25, Rs Cr)<\/td>2412.69<\/td><\/tr>
Quarterly Sales Variation (%)<\/td>20.54<\/td><\/tr>
ROCE (%)<\/td>46.63<\/td><\/tr><\/tbody><\/table>
Source: Screener.in<\/a> (09-01-2025)<\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

CG Power & Industrial Solutions has consistently performed well among mid cap stocks, with steady financials that make it a prominent name in mid market cap stocks. CG Power & Industrial Solutions has a market price of Rs. 678.90 and a P\/E ratio of 116.03, with a market capitalization of Rs. 1,03,906.14 crore. The company reported a quarterly net profit of Rs. 219.63 crore, though it saw a slight decline of 1.77% compared to the previous quarter. Its quarterly sales were Rs. 2,412.69 crore, representing a growth of 20.54%. The return on capital employed (ROCE) for CG Power is a remarkable 46.63%.<\/p>\n\n\n\n

Lupin<\/strong><\/h2>\n\n\n\n
Metric<\/td>Value<\/td><\/tr>
CMP (Rs)<\/td>2250.40<\/td><\/tr>
P\/E Ratio<\/td>39.09<\/td><\/tr>
Market Cap (Rs Cr)<\/td>102659.62<\/td><\/tr>
Dividend Yield (%)<\/td>0.36<\/td><\/tr>
Net Profit (Q2 FY25, Rs Cr)<\/td>859.48<\/td><\/tr>
Quarterly Profit Variation (%)<\/td>74.12<\/td><\/tr>
Sales (Q2 FY25, Rs Cr)<\/td>5672.73<\/td><\/tr>
Quarterly Sales Variation (%)<\/td>12.59<\/td><\/tr>
ROCE (%)<\/td>15.72<\/td><\/tr><\/tbody><\/table>
Source: Screener.in<\/a> (09-01-2025)<\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Lupin is a well-recognized name among mid market cap stocks in the pharmaceutical sector. Its growth trajectory places it among the top-performing mid cap stocks. Lupin has a current market price of Rs. 2250.40 and a P\/E ratio of 39.09, with a market capitalization of Rs. 1,02,659.62 crore. The company reported a quarterly net profit of Rs. 859.48 crore, reflecting a growth of 74.12%. Quarterly sales were Rs. 5,672.73 crore, indicating a sales growth of 12.59%. Its return on capital employed (ROCE) stands at 15.72%.<\/p>\n\n\n\n

Oracle Financial Services<\/strong><\/h2>\n\n\n\n
Metric<\/td>Value<\/td><\/tr>
CMP (Rs)<\/td>11719.75<\/td><\/tr>
P\/E Ratio<\/td>40.76<\/td><\/tr>
Market Cap (Rs Cr)<\/td>101715.50<\/td><\/tr>
Dividend Yield (%)<\/td>2.05<\/td><\/tr>
Net Profit (Q2 FY25, Rs Cr)<\/td>577.70<\/td><\/tr>
Quarterly Profit Variation (%)<\/td>38.39<\/td><\/tr>
Sales (Q2 FY25, Rs Cr)<\/td>1673.90<\/td><\/tr>
Quarterly Sales Variation (%)<\/td>15.88<\/td><\/tr>
ROCE (%)<\/td>39.54<\/td><\/tr><\/tbody><\/table>
Source: Screener.in<\/a> (09-01-2025)<\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Oracle Financial Services<\/a> is a standout performer among mid market cap stocks in the IT sector. Its financial performance continues to make it a favorite in mid cap stocks. Oracle Financial Services has a market price of Rs. 11,719.75 and a P\/E ratio of 40.76, with a market capitalization of Rs. 1,01,715.50 crore. The company reported a quarterly net profit of Rs. 577.70 crore, showcasing a profit growth of 38.39%. Its quarterly sales stood at Rs. 1,673.90 crore, reflecting a growth of 15.88%. Oracle\u2019s return on capital employed (ROCE) is a strong 39.54%.<\/p>\n\n\n\n

Polycab India<\/strong><\/h2>\n\n\n\n
Metric<\/td>Value<\/td><\/tr>
CMP (Rs)<\/td>6764.00<\/td><\/tr>
P\/E Ratio<\/td>56.60<\/td><\/tr>
Market Cap (Rs Cr)<\/td>101573.95<\/td><\/tr>
Dividend Yield (%)<\/td>0.44<\/td><\/tr>
Net Profit (Q2 FY25, Rs Cr)<\/td>445.21<\/td><\/tr>
Quarterly Profit Variation (%)<\/td>3.35<\/td><\/tr>
Sales (Q2 FY25, Rs Cr)<\/td>5498.42<\/td><\/tr>
Quarterly Sales Variation (%)<\/td>30.37<\/td><\/tr>
ROCE (%)<\/td>31.33<\/td><\/tr><\/tbody><\/table>
Source: Screener.in<\/a> (09-01-2025)<\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Polycab India consistently delivers excellent results, cementing its place among mid cap stocks. It remains a leader in mid market cap stocks for the electrical and industrial products sector. Polycab India has a market price of Rs. 6764.00 and a P\/E ratio of 56.60, with a market capitalization of Rs. 1,01,573.95 crore. It reported a net profit of Rs. 445.21 crore in Q2 FY25, with a modest profit growth of 3.35%. Its quarterly sales stood at Rs. 5,498.42 crore, reflecting a growth of 30.37%. The return on capital employed (ROCE) is 31.33%.<\/p>\n\n\n\n

Dixon Technologies<\/strong><\/h2>\n\n\n\n
Metric<\/td>Value<\/td><\/tr>
CMP (Rs)<\/td>16835.05<\/td><\/tr>
P\/E Ratio<\/td>180.38<\/td><\/tr>
Market Cap (Rs Cr)<\/td>101126.02<\/td><\/tr>
Dividend Yield (%)<\/td>0.03<\/td><\/tr>
Net Profit (Q2 FY25, Rs Cr)<\/td>411.70<\/td><\/tr>
Quarterly Profit Variation (%)<\/td>119.30<\/td><\/tr>
Sales (Q2 FY25, Rs Cr)<\/td>11534.08<\/td><\/tr>
Quarterly Sales Variation (%)<\/td>133.33<\/td><\/tr>
ROCE (%)<\/td>29.16<\/td><\/tr><\/tbody><\/table>
Source: Screener.in<\/a> (09-01-2025)<\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Dixon Technologies is a major player in mid cap stocks, particularly in electronics manufacturing. Its remarkable growth secures its position among mid market cap stocks. Dixon Technologies, with a market price of Rs. 16,835.05 and a P\/E ratio of 180.38, has a market capitalization of Rs. 1,01,126.02 crore. The company reported a net profit of Rs. 411.70 crore, reflecting a remarkable growth of 119.30%. Quarterly sales were Rs. 11,534.08 crore, showcasing a growth of 133.33%. Its return on capital employed (ROCE) is 29.16%.<\/p>\n\n\n\n

Persistent Systems<\/strong><\/h2>\n\n\n\n
Metric<\/td>Value<\/td><\/tr>
CMP (Rs)<\/td>6162.40<\/td><\/tr>
P\/E Ratio<\/td>77.80<\/td><\/tr>
Market Cap (Rs Cr)<\/td>95914.77<\/td><\/tr>
Dividend Yield (%)<\/td>0.42<\/td><\/tr>
Net Profit (Q2 FY25, Rs Cr)<\/td>325.00<\/td><\/tr>
Quarterly Profit Variation (%)<\/td>23.45<\/td><\/tr>
Sales (Q2 FY25, Rs Cr)<\/td>2897.15<\/td><\/tr>
Quarterly Sales Variation (%)<\/td>20.13<\/td><\/tr>
ROCE (%)<\/td>29.17<\/td><\/tr><\/tbody><\/table>
Source: Screener.in<\/a> (09-01-2025)<\/figcaption><\/figure>\n\n\n\n

<\/p>\n\n\n\n

Persistent Systems is a leading name in mid cap stocks within the IT sector. It also ranks highly among mid market cap stocks due to its financial performance and market presence. Persistent Systems has a market price of Rs. 6162.40 and a P\/E ratio of 77.80, with a market capitalization of Rs. 95,914.77 crore. The company reported a quarterly net profit of Rs. 325.00 crore, reflecting a growth of 23.45%. Its quarterly sales stood at Rs. 2,897.15 crore, indicating a growth of 20.13%. Persistent Systems has a return on capital employed (ROCE) of 29.17%.<\/p>\n\n\n\n

Conclusion<\/strong><\/h3>\n\n\n\n

The financial metrics of these ten mid cap stocks showcase their growth potential and stability across various sectors. As significant players in the mid market cap stocks category, they highlight the dynamism and opportunities that may be available in this segment.<\/p>\n\n\n

Related Posts<\/h3>